Skip to content

BioCorRx Inc.: 10-Q filed 2021-11-15

What BioCorRx Inc. reported in its quarterly report filed 2021-11-15 (fiscal Q3 2021): 36 published measures, 102 facts as tagged in accession 0001477932-21-008392.

This filing

Form
10-Q (quarterly report)
Filed
2021-11-15
Fiscal period
fiscal Q3 2021
Accession
0001477932-21-008392 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BioCorRx Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-09-301,585,254USD
At 2020-12-311,827,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-09-307,388,472USD
At 2020-12-316,037,353USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-09-30-5,803,218USD
At 2021-06-30-4,491,381USD
At 2021-03-31-3,486,162USD
At 2020-12-31-4,210,353USD
At 2020-09-30-3,403,489USD
At 2020-06-30-2,689,320USD
At 2020-03-31-2,019,470USD
At 2019-12-31-1,058,886USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-09-30745,457USD
At 2020-12-31592,053USD
At 2020-09-30936,209USD
At 2019-12-312,645,852USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-1,363,237USD92
2021-01-01 to 2021-09-30-4,009,205USD273
2021-04-01 to 2021-06-30-1,061,905USD91
2021-01-01 to 2021-03-31-1,584,063USD90
2020-07-01 to 2020-09-30-785,172USD92
2020-01-01 to 2020-09-30-2,601,839USD274
2020-04-01 to 2020-06-30-738,479USD91
2020-01-01 to 2020-03-31-1,078,188USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-2,890,034USD273
2020-01-01 to 2020-09-30-1,810,543USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2021-07-01 to 2021-09-308,817USD92
2021-01-01 to 2021-09-3034,659USD273
2020-07-01 to 2020-09-3029,809USD92
2020-01-01 to 2020-09-30100,399USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-09-303,081,440USD273
2020-01-01 to 2020-09-30107,300USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-38,002USD273
2020-01-01 to 2020-09-30-6,400USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-09-30-68,695,650USD
At 2020-12-31-64,688,311USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2021-01-01 to 2021-09-301,073,631shares273
2020-01-01 to 2020-09-301,143,631shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-09-30109,411USD
At 2020-12-31128,605USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-09-30166,340USD273
2020-01-01 to 2020-09-30257,236USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-1,634,649USD92
2021-01-01 to 2021-09-30-4,177,271USD273
2020-07-01 to 2020-09-30-2,052,858USD92
2020-01-01 to 2020-09-30-5,724,741USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-09-30971,628USD
At 2020-12-31974,925USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-09-304,068,516USD
At 2020-12-313,052,374USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-09-301,506,087USD
At 2020-12-311,180,703USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2021-09-3011,680USD
At 2020-12-3112,564USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-07-01 to 2021-09-301,643,466USD92
2021-01-01 to 2021-09-304,211,930USD273
2020-07-01 to 2020-09-302,082,667USD92
2020-01-01 to 2020-09-305,825,140USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2021-07-01 to 2021-09-301,022USD92
2021-01-01 to 2021-09-303,450USD273
2020-07-01 to 2020-09-3016,550USD92
2020-01-01 to 2020-09-3066,994USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-07-01 to 2021-09-30589,985USD92
2021-01-01 to 2021-09-301,371,484USD273
2020-07-01 to 2020-09-301,289,366USD92
2020-01-01 to 2020-09-303,344,970USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-09-306,642,279shares
At 2020-12-315,463,444shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-09-3062,881,494USD
At 2020-12-3160,466,333USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2021-09-30-5,685,898USD
At 2020-12-31-4,094,899USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-09-30412,030USD
At 2020-12-31489,536USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2021-09-30347,098USD
At 2020-12-31435,405USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-09-30194,551USD
At 2020-12-31192,535USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-09-3085,140USD
At 2020-12-3163,930USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2021-09-300USD
At 2020-12-31176,850USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-07-01 to 2021-09-30892,232USD92
2021-01-01 to 2021-09-302,638,051USD273
2020-07-01 to 2020-09-30757,582USD92
2020-01-01 to 2020-09-302,355,670USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-07-01 to 2021-09-306,663USD92
2021-01-01 to 2021-09-3021,211USD273
2020-07-01 to 2020-09-307,084USD92
2020-01-01 to 2020-09-3021,258USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-07-01 to 2021-09-30271,412USD92
2021-01-01 to 2021-09-30168,066USD273
2020-07-01 to 2020-09-301,267,686USD92
2020-01-01 to 2020-09-303,122,902USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2021-01-01 to 2021-09-300USD273
2020-01-01 to 2020-09-300USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2021-01-01 to 2021-09-300USD273
2020-01-01 to 2020-09-300USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-01-01 to 2021-09-302,250,000USD273
2020-01-01 to 2020-09-300USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-09-30500USD273
2020-01-01 to 2020-09-30750USD274

Inspect the source

Entity
BioCorRx Inc. / CIK 0001443863
Captured
2026-09-20T09:04:22.712Z
SEC response SHA-256
ac5d4257d7a196e773d03095d841b6e99a8b7a937efc54ce0410975e44478703

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001443863.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))